The importance of accurate treatment planning, delivery, and dose verification  by Malicki, Julian
ET
a
I
r
n
r
f
i
a
n
l
c
a
m
c
I
n
t
c
o
s
n
m
n
p
a
f
a
t
w
ﬁ
c
i
s
e
r
e
r
t
s
treports of practical oncology and radiotherapy 1 7 ( 2 0 1 2 ) 63–65
Available  online  at  www.sciencedirect.com
jou rn al h om epa ge: ht tp : / /www.e lsev ier .com/ locate / rpor
ditorialhe  importance  of  accurate  treatment  planning,  delivery,
nd dose  veriﬁcationn recent years, the spectacular technological advances in
adiotherapy have generated much enthusiasm.1 Newer tech-
iques take advantage of increased computing power and
eal-time imaging to provide pinpoint accuracy and dose con-
ormity. The most widely adopted of the new techniques
s undoubtedly intensity-modulated radiation therapy (IMRT)
nd variations thereof. Described as “perhaps the most sig-
iﬁcant technical advances in radiation therapy since the
inear accelerator”, IMRT  gives us the ability to deliver highly
onformal nonconvex dose distributions to the target with
stonishing precision.2 Compared to 3D-CRT, IMRT  offers
any advantages, particular better dose distribution in con-
ave target volumes and lower doses to organs at risk (OAR).3,4
MRT  is surely an immense technological leap forward, though
ot without certain risks.
All radiotherapy involves risk because even a small error in
reatment planning, delivery, or dosimetry can lead to negative
onsequences. This is because the human body is a complex
rganism and tumors are often located in close proximity to
ensitive normal tissues and critical organs. For this reason,
ovel technologies that allow us to treat and cure patients with
inimal adverse effects are very welcome. Unfortunately, the
ewer techniques are highly complex, thus increasing the
otential for error. All modern radiation therapy techniques
re heavily reliant not only on technology, but also on input
rom human experts: the radiation oncologist must locate
nd contour the target area as accurately as possible; then,
he medical physicist needs to design an optimal plan which
ill deliver the required dose while sparing healthy tissue;
nally, the technologist must make sure that the patient is
orrectly positioned before treatment begins. All of these myr-
ad steps are susceptible to errors that may occur due to poor
afety or training procedures, software ﬂaws, or calibration
rrors.5 Indeed, a very critical New York Times investigation6
eported on the sometimes devastating consequences of such
rrors (though it must be said that most of the mistakes
eported by the NY Times could have been prevented by bet-
er quality control, and were not due to the technology per
e). Quality assurance (QA) has long been an integral part of
he ﬁeld of radiation oncology, although interest has increasedsharply in recent years in response to the safety challenges
presented by novel technologies and automated radiotherapy
techniques.7,8
The aim of the present editorial is not to focus on human
mistakes related to poor quality control, but rather to exam-
ine the importance of detecting, minimizing, and eliminating
the (usually) small errors in planning, patient set-up, and
delivery that can result in harmful irradiation outside of the
target area. IMRT  and other advanced techniques (image-
guided RT, stereotactic radiosurgery, etc.) represent an entirely
new paradigm that requires extensive knowledge and under-
standing of the latest imaging systems, setup uncertainties,
radiobiological response of healthy tissues, three-dimensional
(3D) dose calculation and optimization, variable intensity
beam delivery, and internal organ motion.9 In an age in which
steep dose gradients are commonplace, it is imperative that
the radiation be delivered as precisely as possible.
One way to ensure accurate delivery is to account for
internal organ motion. This requires real-time imaging that
allows for the radiation beam to be continually adjusted and
aligned with the tumor. When performed successfully, this
method can improve accuracy and reduce doses to surround-
ing tissues, thereby increasing local control while reducing
toxicity.10 In recent years, interest in understanding and
addressing organ motion during radiotherapy has increased
dramatically. Organ motion presents a complex challenge to
planning and delivery of radiotherapy, and it is particularly
demanding when it comes to complex treatments such as
IMRT.
The inherent complexity in planning and delivery of IMRT
requires a comprehensive QA program to prevent errors. At
present, QA in IMRT involves QA of the treatment planning
and delivery system, in addition to patient-speciﬁc quality
control. IMRT QA is similar to that used for conventional 3D
conformal radiation therapy, with the main difference being
that the number of parameters requiring veriﬁcation is much
greater for IMRT: complex calculations are required to con-
trol beam intensity and each IMRT ﬁeld often includes many
small irregular off-axis ﬁelds which provide more  conformal
dose coverage but also increase complexity. As a result, dose
nd ra64  reports of practical oncology a
calculation and delivery accuracy must be validated for both
treatment planning and delivery, and the overall accuracy of
irradiation is highly dependent on uncertainties in both the
planning and delivery processes.11 Fortunately, the problems
with providing appropriate QA for IMRT  have been thoroughly
studied and presented in numerous publications. Methodolo-
gies and tools that support safe and accurate IMRT have been
developed and checked, and organizations such as the ESTRO
and ASTRO publish guides to assist with these procedures.12,13
In an ideal world, integrated, dedicated planning and deliv-
ery systems would be available to all. However, such systems
are expensive and often cost-prohibitive. However, in a inter-
esting paper14 published in the journal Radiology & Oncology,
Das et al. describe how they were able to create a fully
electronic IMRT  QA process in a network of independent treat-
ment planning, record and verify, and delivery systems. These
authors were able to successfully implement a paperless and
ﬁlmless IMRT  QA process. These authors found that their sys-
tem allowed them to ensure proper dose delivery to patients.
They conclude that for centers without an integrated plan-
ning, verifying, and delivery system, a completely electronic
IMRT  QA process is still possible.
At our journal, Reports of Practical Oncology and Radio-
therapy, we believe that areas related to accuracy in planning,
delivery, and veriﬁcation are sometimes underappreciated. As
a result, we  frequently publish articles that address these cru-
cial aspects of quality control and accuracy in radiotherapy.
For example, one recent article investigated the use of an
electronic portal imaging device (EPID) for quality assurance
in Volumetric Modulated Arc Therapy (VMAT).15 The authors
emphasize the importance of an accurate and reproducible
patient set-up as absolutely essential to precise delivery of
fractionated radiotherapy, which, in this case, they achieved
through the use of the AlignRT software in breast cancer
patients.16
Another recent study17 evaluated an anatomy-based
method of IMRT  veriﬁcation. The authors explain that during
a proper execution of dynamic multileaf collimated (dMCL)
treatment plans, the radiation dose accumulated by tissue
is often widely different than expected. According to these
authors, conventional dosimetric QA procedures give only
a partial picture of the quality of IMRT  treatment because
their purely quantitative measurements are conﬁned to the
detector’s total area rather than the actually irradiated vol-
ume. They developed a dynamic plan veriﬁcation procedure
that allows for visualization of potential dose distribution
anomalies and which can identify exactly which tissue these
anomalies occur. The authors created their own proprietary
software (GammaEval) to evaluate over 150 dose distribution
maps. This novel method permits precise identiﬁcation of
deviations between predicted and acquired dose distributions
(registered by portal and ﬁlm).
Perhaps the main concern about IMRT  is “leakage” of the
dose to healthy surrounding tissues. This is particularly rel-
evant in high-risk areas with many  OARs located nearby, as
occurs in gynecological cancers. One approach to minimizing
this problem can be seen in a recent study that compared 6 MV
vs. 15 MV  photon energy plans for IMRT  in cervix cancer.18
The authors found that the 6 MV  plan resulted in compara-
ble coverage of the planning target volume (PTV) with betterdiotherapy 1 7 ( 2 0 1 2 ) 63–65
OAR sparing. Another notable study compared IMRT and
Cyberknife treatment plans for localized prostate cancer.19 In
that study, the authors reported that both systems are good at
creating highly conformal volumetric dose distributions, with
good OAR sparing.
Discrepancies between estimated and delivered doses con-
tinue to present some difﬁculties. To address this issue, Sardari
et al. used a Geant4-based software application to simulate
the absorbed dose distribution in a water phantom, ﬁnding
that measured and calculated dose values showed good agree-
ment with this technique.20 Similarly, Slosarec et al. reported
on a procedure for the use of EPID for in vivo dosimetry with
the RapidArc technique.21 Numerous methods can be used
for dose veriﬁcation. One recent study evaluated the inﬂuence
of different types of detectors on measured modulated dose
distributions. These authors reported that radiographic ﬁlm
can be used for the dosimetry of compensated high energy
photon beams.22 Another study evaluated dosimetry in a 320
detector row CT scanner unit.23 These are but a few exam-
ples of the unending search to improve planning so that
pretreatment calculations better reﬂect actual doses deliv-
ered. Undoubtedly, this is an area that will continue to receive
attention.
Another important obstacle in improving and standardiz-
ing IMRT techniques is the large variability among institutions
in terms of IMRT dose prescription, recording, and delivery.
This heterogeneity makes it difﬁcult to compare clinical out-
comes for IMRT. Das et al.24 recently compared 5 different
centers and found that 46% of the patients received a maxi-
mum dose that was more  than 10% higher than the prescribed
dose, while 63% of the patients received a dose that was
more than 10% lower than the prescribed dose. Moreover,
the recorded isocenter dose varied from prescription for eval-
uated tumor localizations and treatment planning systems.
They conclude that substantial variation in the prescribed and
delivered doses exists among medical institutions, and they
call for national and/or international guidelines for dose pre-
scription, planning, and reporting for IMRT.
In this era of dose escalation, complex technology, and
advanced computer algorithms, sometimes it is important to
take a step back and be creative in our approach to improv-
ing treatments. Recently, one group of researchers presented
their innovative approach to reducing toxicity to OARs in
prostate cancer.25 In this 24 patient study, two  treatment plans
(Tomotherapy) were performed for each patient: one in the
supine and one in the prone position. These authors found
that prone position was associated with lower doses in OARs,
especially in the rectum. They conclude that, in patients irradi-
ated to prostate and seminal vesicles, the prone position may
spare the rectum and bladder.
Throughout this editorial, the point has been made that
present day radiotherapy is extraordinarily complex and
therefore requires great diligence to assure accurate deliv-
ery in accordance with the treatment plan. Although much
progress has been made, much remains to be done. At Reports
of Practical Oncology and Radiotherapy, we are doing our best
to publish relevant papers on this critical subject. Although I
agree with Chung et al.26 that “treatment planning and deliv-
ery in radiation therapy will be never perfect”, I would hasten
to add that we  must continue doing our best to make it so.
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